Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Severe and Critical COVID-19 Condition

NCT05501418 is registered in ClinicalTrials.gov with Ever Supreme Bio Technology Co., Ltd. as lead sponsor.

NCT NCT05501418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05501418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Severe and Critical COVID-19 Condition
Lead sponsor
Ever Supreme Bio Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 5, 2020
Completion date
December 31, 2027
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection